Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study
Miao et al.,
Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19:..,
Frontiers in Endocrinology, doi:10.3389/fendo.2022.1002834
Retrospective 4,462 COVID+ diabetes patients in the USA, showing no significant difference in outcomes with metformin use.
risk of death, 1.3% lower, RR 0.99, p = 0.91, treatment 233 of 796 (29.3%), control 236 of 796 (29.6%), NNT 265, propensity score matching.
|
hospitalization time, 4.9% lower, relative time 0.95, p = 0.23, treatment 796, control 796, propensity score matching.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Miao et al., 9 Nov 2022, retrospective, USA, peer-reviewed, 6 authors, study period 1 January, 2020 - 7 May, 2020.
Abstract: TYPE Original Research
PUBLISHED 09 November 2022
DOI 10.3389/fendo.2022.1002834
OPEN ACCESS
EDITED BY
Åke Sjöholm,
Gävle Hospital, Sweden
REVIEWED BY
Fahad Aljuraibah,
King Saud bin Abdulaziz University for
Health Sciences, Saudi Arabia
Wenfang Xia,
Huazhong University of Science and
Technology, China
Metformin use and mortality
and length of stay among
hospitalized patients with type 2
diabetes and COVID-19: A
multiracial, multiethnic, urban
observational study
*CORRESPONDENCE
Claudene J. George
clgeorge@montefiore.org
†
These authors have contributed
equally to this work and share
first authorship
SPECIALTY SECTION
This article was submitted to
Clinical Diabetes,
a section of the journal
Frontiers in Endocrinology
RECEIVED 25 July 2022
ACCEPTED 21 October 2022
PUBLISHED 09 November 2022
CITATION
Miao E, Zhang K, Liu J, Lin J, Yoo D
and George CJ (2022) Metformin use
and mortality and length of stay
among hospitalized patients with type
2 diabetes and COVID-19: A
multiracial, multiethnic, urban
observational study.
Front. Endocrinol. 13:1002834.
doi: 10.3389/fendo.2022.1002834
COPYRIGHT
© 2022 Miao, Zhang, Liu, Lin, Yoo and
George. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.
Frontiers in Endocrinology
Emily Miao 1†, Kaleena Zhang 1†, Jianyou Liu 2, Juan Lin 2,
Donna Yoo 1 and Claudene J. George 3*
1
Albert Einstein College of Medicine Bronx, New York, NY, United States, 2 Department of
Epidemiology and Population Health, Albert Einstein College of Medicine Bronx, New York,
NY, United States, 3 Montefiore Medical Center, Division of Geriatrics, Albert Einstein College of
Medicine Bronx, New York, NY, United States
Introduction: Diabetes mellitus is a common comorbidity among patients with
coronavirus disease 2019 (COVID-19). Diabetic patients with COVID-19 have a
two-fold increased risk of death and tend to have more severe infection
compared to the general population. Metformin, a first-line medication for
diabetes management, has anti-inflammatory and immunomodulatory effects.
Previous studies focusing on metformin and COVID-19 clinical outcomes have
had mixed results, with some showing a mortality benefit or decreased
complications with metformin use. To date, few studies have analyzed such
outcomes among a diverse, multiracial community.
Methods: This was a retrospective review of patients with Type 2 diabetes and a
confirmed COVID-19 infection admitted to an urban academic medical center
from January 1, 2020 to May 7, 2020. Baseline characteristics were collected.
The primary outcomes of the study were in-hospital mortality and length of
stay (LOS).
Results: A total of 4462 patients with Type 2 diabetes and confirmed COVID-19
were identified. 41.3% were Black, and 41.5% were Hispanic. There were 1021
patients in the metformin group and 3441 in the non-metformin group. Of note,
more participants in the metformin group had comorbid disease and/or advanced
diabetes. We found no statistically significant differences between the metformin
and non-metformin group in in-hospital mortality (28.1% vs 25.3%, P=0.08) or
length of hospital..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit